CosmosID
CosmosID is a distinguished provider of end-to-end metagenomics services, specializing in unlocking the full potential of the microbiome for academia, industry, and clinical applications. The company’s core offering revolves around high-quality sequencing data combined with an industry-leading, four-time award-winning bioinformatics pipeline. This proprietary platform is validated for superior sensitivity and precision, enabling strain-level resolution for a multi-kingdom analysis that includes bacteria, viruses, phages, fungi, and protists, as well as the detection of AMR and Virulence genes. CosmosID supports a comprehensive range of metagenomic approaches, including both Amplicon Sequencing and Full Genome Sequencing, and extends its services into genome analysis and phylogenetic analysis. Operating a CLIA/GCP/HIPAA-compliant facility with over 12 years of experience, CosmosID delivers standardized and validated metagenomics analysis, providing clients with unparalleled confidence in their data. The company has a proven track record of supporting organizations in publishing new studies, developing new products and therapeutics, and diagnosing patients, positioning it at the forefront of advanced microbiome analysis and discovery services globally.
Latest Market Research Report on Microbiome Sequencing Services Download PDF Brochure Now
Zymo Research Corp.
Zymo Research Corp. is a key player in the microbiome sequencing services market, known for its focus on high-fidelity, accurate microbiome quantification, and industry-leading turnaround times. The company provides a comprehensive suite of Next-Generation Sequencing (NGS) services tailored for any sample type. Its core offerings include various amplicon sequencing approaches (such as 16S/ITS Targeted Amplicon Sequencing and Full-Length 16S), alongside powerful Shotgun Metagenomic Sequencing, Metatranscriptomic Sequencing, and custom solutions. Zymo Research has invested significant effort into developing a high-fidelity pipeline that minimizes bias, ensuring superior data quality. A notable feature of their service is the use of the world’s first commercial mock community microbiome standard for quality control, which helps validate the accuracy of their results. The company streamlines the research process through its NGS Service Portal and also provides essential tools like sample collection devices for unbiased sample storage and transport. By consistently delivering publication-ready data and offering expertise across various sequencing platforms, Zymo Research is a trusted partner for researchers seeking reliable and comprehensive microbiome analysis.
Illumina
Illumina, Inc. is a global technology powerhouse whose sequencing platforms form the foundational backbone for the majority of high-throughput microbiome sequencing services worldwide. While primarily a manufacturer of sequencing instruments, reagents, and associated consumables, the company is central to the microbiome services industry by providing the market’s dominant short-read sequencing technology. Their platforms, suchor the NovaSeq and MiSeq series, are universally utilized by core labs and service providers to execute both 16S rRNA gene-targeted sequencing for taxonomic profiling and shotgun metagenomic sequencing for functional and taxonomic analysis. Illumina’s continuous innovation in sequencing chemistry and system integration ensures the high-throughput capacity, speed, and accuracy necessary for large-scale microbiome studies. The company’s strong ecosystem, including comprehensive workflow solutions and robust bioinformatics tools, makes it an indispensable partner for organizations performing cancer microbiome profiling, population genomics, and infectious disease research, thereby solidifying its status as a foundational leader in the microbiome sequencing services market.
CD Genomics
CD Genomics is a dedicated provider of next-generation sequencing (NGS) services, offering researchers a high-resolution, culture-independent approach to explore the structure and function of microbial communities. The company utilizes advanced sequencing technologies from both Illumina and PacBio to ensure the accuracy and reliability of its results. Their service portfolio is extensive, covering a complete spectrum of microbial analysis, including standard microbial sequencing, viral metagenomic sequencing for characterizing the entire viral population, and metatranscriptomic sequencing to understand the functional dynamics of microbial communities. A specialized offering is their absolute quantitative amplicon sequencing, which provides researchers with the exact counts of target microbial sequences. CD Genomics pairs its efficient sequencing procedures with stringent quality controls and comprehensive bioinformatics analyses. The company’s focus on using cutting-edge sequencing technologies and generating detailed, publication-ready data positions it as an expert partner for researchers seeking vital insights into complex microbial ecosystems for various ecological, virological, and biological studies.
BGI Genomics Co., Ltd.
BGI Genomics Co., Ltd. is a leading global provider of sequencing and omics services, playing a significant role in the microbiome sequencing market through its large-scale capacity and competitive pricing model. The company provides access to advanced genomic technologies that support a broad range of applications, including extensive cancer microbiome research and population genomics, particularly within the Asia-Pacific region. BGI’s services leverage proprietary sequencing platforms and sophisticated cloud-based bioinformatics tools to process high volumes of samples efficiently and cost-effectively. They offer comprehensive solutions for various oncological studies, such as stratified analyses and biomarker studies, by supporting both 16S rRNA and shotgun metagenomic sequencing. BGI’s commitment to large-scale operations and continuous technological development has made it a key player in democratizing access to advanced microbiome research, enabling scientists globally to conduct large cohort studies that translate complex microbiome data into meaningful scientific and clinical insights.
Pacific Biosciences of California, Inc.
Pacific Biosciences (PacBio) is a pioneering company in the sequencing industry, specializing in long-read sequencing technologies which are becoming increasingly critical for comprehensive microbiome analysis. Unlike short-read technologies, PacBio’s platforms, such as those enabled by HiFi sequencing, generate long, highly accurate reads that are essential for resolving complex microbial communities. This capability is paramount for achieving full-length microbial genome sequencing and providing high-resolution insights into the functional diversity within tumor microenvironments and other complex samples. The long-read data allows for precise functional profiling and patient-specific microbiome characterization, which is particularly valuable for the discovery of novel microbial biomarkers relevant to diseases like breast and colorectal cancers. By pushing the boundaries of read length and accuracy, PacBio provides service providers and research institutions with a powerful tool to overcome the limitations of traditional short-read methods, significantly enhancing the depth and relevance of translational and clinical microbiome studies.
Oxford Nanopore Technologies Ltd.
Oxford Nanopore Technologies (ONT) is a prominent innovator in the sequencing space, distinguished by its development of portable, real-time sequencing devices that are highly influential in the microbiome services market. The company’s technology offers unique advantages, particularly its ability to deliver ultra-long reads which are crucial for characterizing complete microbial genomes and complex community structures. This capability is essential for in-depth functional profiling and accurate, patient-specific microbiome characterization. Furthermore, the small size and real-time data streaming capabilities of its devices, such as the MinION, open new avenues for decentralized and rapid oncology studies and field research. ONT’s growing ecosystem of adaptable tools and bioinformatics solutions allows service labs to accelerate adoption within translational and clinical microbiome applications. By providing an alternative to traditional, large-scale sequencers, Oxford Nanopore empowers researchers to conduct nuanced analysis of microbial communities, driving forward discovery in personalized medicine and fundamental biological research.
Igenbio, Inc.
Igenbio, Inc. is a leader in genomic analysis and services with a strong focus on the microbial domain, offering comprehensive microbiome sequencing and analysis services backed by deep bioinformatics expertise. The company’s services are built on decades of experience in biology and computer science, leveraging their proprietary informatics platform, ERGO, as the basis for major groundbreaking research. Igenbio provides a wide array of genomic services, including Microbiome Sequencing and Analysis, Whole Genome Sequencing (WGS), RNA sequencing (RNA-Seq), Genome Assembly and Annotation, and custom bioinformatics solutions. They specialize in metagenome/microbiome analysis, offering detailed insights like Metabolic Reconstruction and Differential Gene Expression Analysis. By combining high-quality sequencing with expert statistical analysis and proprietary computational tools, Igenbio delivers reliable scientific results for academic, governmental, and industrial clients, aiding in complex studies, including microbial metabolic engineering and the development of new therapeutics.
Clinical Microbiomics
Clinical Microbiomics is a specialized Contract Research Organization (CRO) dedicated to delivering high-quality, clinical-grade microbiome analysis services for the pharmaceutical, biotech, and food industries. The company focuses on the stringent requirements of clinical trials and diagnostic development, ensuring regulatory compliance and data integrity. They offer end-to-end services, from study design and sample preparation to advanced bioinformatics and biostatistics, supporting both 16S rRNA gene sequencing and shotgun metagenomics. Their expertise lies in translating complex microbial data into actionable clinical insights, which is crucial for the development of microbiome-based therapeutics and diagnostics. By specializing in the intersection of microbiology, genomics, and clinical science, Clinical Microbiomics is a critical partner for organizations needing reliable, standardized, and scalable services to advance their products from discovery through regulatory approval.
Microbiome Insights
Microbiome Insights is a leading global provider of services specifically focused on high-quality microbiome analysis for industry, academia, and clinical research. The company offers a complete suite of services designed to help researchers efficiently conduct studies on microbial communities across diverse environments, including the human gut, soil, and animal hosts. Their offerings typically include 16S rRNA gene sequencing for taxonomic profiling, ITS sequencing for fungi, and shotgun metagenomic sequencing for deep functional and taxonomic analysis. They are recognized for providing comprehensive project support, from initial study design consultation and sample processing to advanced statistical analysis and bioinformatics interpretation. By prioritizing rapid turnaround times, rigorous quality control, and expert support, Microbiome Insights enables clients worldwide to accelerate their research, biomarker discovery, and product development in areas such as personalized nutrition, therapeutic development, and environmental science.
Latest Market Research Report on Microbiome Sequencing Services Download PDF Brochure Now